Multiple primary carcinoma which is the same organ of the same patient or multiple organs, tissues has occurred two or more than two kinds of the primary malignant tumor. All cancer at the same time or 6 months from d...Multiple primary carcinoma which is the same organ of the same patient or multiple organs, tissues has occurred two or more than two kinds of the primary malignant tumor. All cancer at the same time or 6 months from diagnosis is called simultaneous multiple primary carcinoma. In this case the patient suffering from cancer including rectal cancer, colon cancer and appendix gastrointestinal stromal tumor(GIST) three primary carcinoma, is simultaneous multiple primary carcinoma and it's extremely rare on the clinical cases. This report address that the incidence of the patient with operation and pathological diagnosis.展开更多
Dear Editor,Primary iliac fossa sarcoma(IFS)is a special type of retroperitoneal sarcoma(RPS),accounting for∼15%of all RPS cases[1].The deep location,large size,and invasion to surrounding tissues and organs are the ...Dear Editor,Primary iliac fossa sarcoma(IFS)is a special type of retroperitoneal sarcoma(RPS),accounting for∼15%of all RPS cases[1].The deep location,large size,and invasion to surrounding tissues and organs are the main causes of unresectability of IFS.All these characteristics are associated with an increased risk of positive surgical margin and a decreased feasibility of adjuvant therapy.In patients with multivisceral and/or vascular involvement,a multivisceral en bloc approach[2]with blood vessel replacement may be required to achieve a negative margin and to improve the quality of resection[3].However,whether these surgical procedures improve prognosis in patients with IFS remain undefined.Moreover,whether aggressive procedures lead to acceptable functional impairment requires validation.In addition,previous studies have reported inconsistent results regarding the role of adjuvant radiotherapy in the treatment of RPS[4].To date,the role of radiotherapy in the local control of IFS remains to be determined.Therefore,we analyzed the clinical features,treatment,and outcomes of IFS patients in an attempt to determine the significant prognostic factors and efficient therapeutics in real clinical practice.展开更多
文摘Multiple primary carcinoma which is the same organ of the same patient or multiple organs, tissues has occurred two or more than two kinds of the primary malignant tumor. All cancer at the same time or 6 months from diagnosis is called simultaneous multiple primary carcinoma. In this case the patient suffering from cancer including rectal cancer, colon cancer and appendix gastrointestinal stromal tumor(GIST) three primary carcinoma, is simultaneous multiple primary carcinoma and it's extremely rare on the clinical cases. This report address that the incidence of the patient with operation and pathological diagnosis.
基金supported by the grants from National Natural Science Foundation of China(No.81302342).
文摘Dear Editor,Primary iliac fossa sarcoma(IFS)is a special type of retroperitoneal sarcoma(RPS),accounting for∼15%of all RPS cases[1].The deep location,large size,and invasion to surrounding tissues and organs are the main causes of unresectability of IFS.All these characteristics are associated with an increased risk of positive surgical margin and a decreased feasibility of adjuvant therapy.In patients with multivisceral and/or vascular involvement,a multivisceral en bloc approach[2]with blood vessel replacement may be required to achieve a negative margin and to improve the quality of resection[3].However,whether these surgical procedures improve prognosis in patients with IFS remain undefined.Moreover,whether aggressive procedures lead to acceptable functional impairment requires validation.In addition,previous studies have reported inconsistent results regarding the role of adjuvant radiotherapy in the treatment of RPS[4].To date,the role of radiotherapy in the local control of IFS remains to be determined.Therefore,we analyzed the clinical features,treatment,and outcomes of IFS patients in an attempt to determine the significant prognostic factors and efficient therapeutics in real clinical practice.
